Leadiant faces Spanish dominance-abuse probe over CTX ‘orphan drug’
MLex Summary: Drugmaker Leadiant Biosciences is now under investigation by Spain's competition authority, to see whether it abused its market power in the production and supply of CDCA-Leadiant, a drug used...To view the full article, register now.
Already a subscriber? Click here to view full article